Metixene


Concise Prescribing Info
Indications/Uses
Parkinson's disease.
Dosage/Direction for Use
Adult : PO Initial: 2.5 mg 3 times/day, may increase up to 15-60 mg/day in divided doses.
Dosage Details
Oral
Monotherapy in Parkinson's disease
Adult: As hydrochloride: Initially, 2.5 mg tid; increase gradually depending on clinical response to a total of 15-60 mg daily in divided doses.
Contraindications
Closed-angle glaucoma, myasthenia gravis; paralytic ileus; pyloric stenosis and prostatic hyperplasia; hyperthyroidism; tachycardia.
Special Precautions
Down's syndrome. Child. Acute MI; cardiac insufficiency; pyrexia. Severe hepatic impairment and renal failure. Pregnancy and lactation.
Adverse Reactions
Dryness of the mouth, constipation, nausea, asthenia, vertigo, blurred vision, ataxia, fever, headache, rash, acute glaucoma.
Overdosage
Symptoms: Dilated and sluggish pupils, warm and dry skin, facial flushing, dryness of mouth, pharynx, nose and bronchi, foul-smelling breath, elevated temperature, tachycardia, cardiac arrhythmias, decreased bowel sounds, urinary retention, delirium, disorientation, anxiety, hallucinations, illusions, confusion, incoherence, agitation, hyperactivity, ataxia, loss of memory, paranoia, combativeness, seizures.
Drug Interactions
Effects may be enhanced by other drugs with antimuscarinic properties e.g. amantadine, antihistamines, phenothiazine antipsychotics and TCAs. MAOIs may possibly enhance antimuscarinic effects. May affect the absorption of other drugs. Antimuscarinics and parasympathomimetics may counteract each other's effects.
Action
Description: Metixene is a tertiary antimuscarinic with both central and peripheral actions. It also has antihistaminic and direct antispasmodic effects.
Pharmacokinetics:
Absorption: Absorbed from the GI tract.
Metabolism: Hepatic via sulfoxydation and N-demethylation.
Excretion: Via urine.
Disclaimer: This information is independently developed by MIMS based on Metixene from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in